文献速递免疫规划卫生政策与健康促进

美国22至26岁男性接种九价人乳头瘤病毒疫苗的成本效果分析

Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
PubMed 文献 · Vaccine · 2018-01-01

该研究更新已发表的九价人乳头瘤病毒疫苗(9vHPV)健康影响与成本效果模型,比较女性12至26岁、男性12至21岁接种与扩展至男性26岁的方案。相比不接种,现行方案每获得一个质量调整生命年(QALY)成本约16600美元(2016年美元);扩展男性接种至26岁每QALY成本为228800美元,多因素敏感性分析范围为137900至367300美元。

要点

  • 女性12至26岁、男性12至21岁接种9vHPV相比不接种每QALY成本约16600美元。
  • 扩展男性接种至26岁每QALY成本为228800美元,敏感性分析范围137900至367300美元。
  • 作者认为该成本效果比不足以为扩展男性接种提供强经济证据,但也不足以排除考虑扩展。

核心结论

  • 作者估计的成本效果比不足以为推荐扩展男性接种提供强经济证据,但也不足以排除考虑扩展男性接种。
  • 由于模型局限性,所获得的宽泛可能结果范围可能低估了真实的不确定性程度。
  • 需要专门纳入男男性行为者(MSM)的模型来更全面评估男性HPV疫苗接种策略。

研究设计与样本

  • 研究更新了一个已发表的九价人乳头瘤病毒疫苗(9vHPV)健康影响与成本效果模型。
  • 分析比较两种策略:女性12至26岁、男性12至21岁接种9vHPV;以及扩展方案包括男性至26岁。
  • 以不接种为对照,评估每获得一个质量调整生命年(QALY)的成本。

主要发现

  • 相比不接种,女性12至26岁、男性12至21岁接种9vHPV每获得一个QALY成本估计为16600美元(2016年美元)。
  • 扩展男性接种至26岁每获得一个QALY成本估计为228800美元。
  • 多因素敏感性分析中,扩展男性接种至26岁的每QALY成本范围为137900至367300美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 模型局限性可能导致所获得的宽泛可能结果范围低估了真实的不确定性程度。
  • 若模型允许疫苗对再感染提供保护,每QALY成本可能低于下限估计值137900美元。
  • 需要专门纳入男男性行为者(MSM)的模型来更全面评估男性HPV疫苗接种策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the United States, routine human papillomavirus (HPV) vaccination is recommended for females and males at age 11 or 12 years; the series can be started at age 9 years. Vaccination is also recommended for females through age 26 years and males through age 21 years. The objective of this study was to assess the health impact and cost-effectiveness of harmonizing female and male vaccination recommendations by increasing the upper recommended catch-up age of HPV vaccination for males from age 21 to age 26 years. METHODS: We updated a published model of the health impact and cost-effectiveness of 9-valent human papillomavirus vaccine (9vHPV). We examined the cost-effectiveness of (1) 9vHPV for females aged 12 through 26 years and males aged 12 through 21 years, and (2) an expanded program including males through age 26 years. RESULTS: Compared to no vaccination, providing 9vHPV for females aged 12 through 26 years and males aged 12 through 21 years cost an estimated $16,600 (in 2016 U.S. dollars) per quality-adjusted life year (QALY) gained. The estimated cost per QALY gained by expanding male vaccination through age 26 years was $228,800 and ranged from $137,900 to $367,300 in multi-way sensitivity analyses. CONCLUSIONS: The cost-effectiveness ratios we estimated are not so favorable as to make a strong economic case for recommending expanding male vaccination, yet are not so unfavorable as to preclude consideration of expanding male vaccination. The wide range of plausible results we obtained may underestimate the true degree of uncertainty, due to model limitations. For example, the cost per QALY might be less than our lower bound estimate of $137,900 had our model allowed for vaccine protection against re-infection. Models that specifically incorporate men who have sex with men (MSM) are needed to provide a more comprehensive assessment of male HPV vaccination strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chesson HW, Meites E, Ekwueme DU, et al. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. Vaccine. 2018. PMID: 29887325. doi:10.1016/j.vaccine.2018.04.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。